A Single Dose of Intravenous Human Amniotic Membrane-Derived Mesenchymal Stem Cells Limits Transmural Infarction, Reduces Fibrosis Size, and Improves Left Ventricular Systolic Function In The Myocardial Ischemic/ Reperfusion Model of Rats

Author(s): Jia-Wei Sung, Yen-Ting Yeh, Fu-Shiang Peng, Yi-Chen Chen, Ai-Hsien Li, Shinn-Chih Wu

Introduction: Human amniotic membrane-derived mesenchymal stem cells (hAMSCs) have been shown with properties of immunomodulation, anti-inflammation, and low immunogenicity, which make them good candidates for cell therapies. In this study, we evaluated the therapeutic effects of Human amniotic membrane-derived mesenchymal stem cells (hAMSCs) in a rat model of myocardial ischemia/reperfusion (I/R).

Methods: Myocardial ischemic/reperfusion was generated in Sprague Dawley rats. hAMSCs were injected into rats tail vein during coronary reperfusion. Dulbecco's phosphate-buffered saline (DPBS) were injected as negative control. Cardiac function was evaluated by echocardiography. Infarct size was analyzed by histochemical staining.

Results: Compared with negative control (DPBS group), hAMSCs group resulted in improvement of cardiac function and smaller infarct size at 28 days post-I/R.

Conclusion: A single dose of intravenous hAMSCs administered at the time of coronary reperfusion prevented transmural infarction, alleviated myocardial loss, and improved left ventricular systolic function in the rat I/R model.